Premium
Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges
Author(s) -
Attucci S,
Carlà V,
Mannaioni G,
Moroni F
Publication year - 2001
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0703904
Subject(s) - nmda receptor , metabotropic receptor , metabotropic glutamate receptor , agonist , glutamate receptor , receptor , long term depression , chemistry , pharmacology , biology , neuroscience , biochemistry , ampa receptor
We measured the effects of agonists and antagonists of metabotropic glutamate (mGlu) receptors (types 1 and 5) on NMDA‐induced depolarization of mouse cortical wedges in order to characterize the mGlu receptor type responsible for modulating NMDA responses. We also characterized a number of mGlu receptor agents by measuring [ 3 H]‐inositol phosphate (IP) formation in cortical slices and in BHK cells expressing either mGlu 1 or mGlu 5 receptors. (S)‐3,5‐dihydroxyphenylglycine (DHPG), an agonist of both mGlu 1 and mGlu 5 receptors, at concentrations ranging from 1 – 10 μ M , enhanced up to 105±15% the NMDA‐induced depolarization. Larger concentrations (100 – 300 μ M ) of the compound were inactive in this test. When evaluated on [ 3 H]‐IP synthesis in cortical slices or in cells expressing either mGlu 1 or mGlu 5 receptors, DHPG responses (1 – 300 μ M ) increased in a concentration‐dependent manner. (RS)‐2‐chloro‐5‐hydroxyphenylglycine (CHPG) and ( S )‐(+)‐2‐(3′‐carboxybicyclo[1.1.1]pentyl)‐glycine (CBPG), had partial agonist activity on mGlu 5 receptors, with maximal effects reaching approximately 50% that of the full agonists. These compounds, however, enhanced NMDA‐evoked currents with maximal effects not different from those induced by DHPG. Thus the enhancement of [ 3 H]‐IP synthesis and the potentiation of NMDA currents were not directly related. 2‐methyl‐6‐(phenylethynyl)‐pyridine (MPEP, 1 – 10 μ M ), a selective mGlu 5 receptor antagonist, reduced DHPG effects on NMDA currents. 7‐(hydroxyimino)cyclopropan[b]‐chromen‐1a‐carboxylic acid ethylester (CPCCOEt, 30 μ M ), a preferential mGlu 1 receptor antagonist, did not reduce NMDA currents. These results show that mGlu 5 receptor agonists enhance while mGlu 5 receptor antagonists reduce NMDA currents. Thus the use of mGlu 5 receptor agents may be suggested in a number of pathologies related to altered NMDA receptor function.British Journal of Pharmacology (2001) 132 , 799–806; doi: 10.1038/sj.bjp.0703904